1 October 2016 Text size Home About us APIs Contract Manufacturing Production R&D Quality Management EHS Orion Corporation News from Fermion Fermion extends its particle engineering capabilities Fermion strengthens its particle engineering capabilities by investing in... (22 August 2016) Fermion In the World’s Forefront of Safety Fermion has attained level I, “In the World’s Forefront of Safety”, in the... (6 June 2016) New regulatory files for hydroxychloroquine and sodium cromoglicate are now available USDMF for Fermion’s hydroxychloroquine sulphate is now available for reference... (8 April 2016) API manufacturing facility expansion, Hanko, Finland 2018 will mark the start of a new era in Fermion’s history as Fermion’s plant... (15 March 2016) Successful ANVISA Inspection at Fermion's API manufacturing plant in Oulu, Finland Fermion passed successfully ANVISA Inspection 2016 with three minor... (4 February 2016) FERMION Manufacturer of Active Pharmaceutical Ingredients (API) for both generic and proprietary drug products since 1970. Contract manufacturing services for APIs including oncology and highly potent compounds. Meet us at: ChemOutsourcing, September 19-21, Parsippany, NY, USA CPhI Europe, October 4-6, Barcelona, Spain CPhI North America, May 16-18, 2017, Philadelphia, USA QUICK LINKS Articles GMP certificates and statements List of API's MSDS Responsible care Standard Sales and Delivery Conditions Fermion Oy, Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland Tel. +358 10 4261 Fax: +358 9 452 1764 VAT Reg. No. FI18552129 e-mail: fermionSales@fermion.fi Contacts

25 October 2016 Text size Home About us APIs Contract Manufacturing Production R&D Quality Management EHS Orion Corporation Route Scouting Process Development Up-scaling Facilities Equipment Reagents and Reaction types Home / R&D Print Research and Development Fermion R&D has the experience from over 40 years API development to give a competitive advantage. Tacit knowledge is combined into an efficient, standardized development scheme saving time and costs. Our core advantages are: - the ability to take a molecule from pre-clinics all the way to Phase IV - highly motivated and well educated personnel with full commitment - dedicated engineer in every project involving upscaling - automation in R&D and production - fast and efficient problem solving - full impurity- and polymorph control - dedicated team for life cycle management to reduce costs of later stage products - strong particle engineering and physical properties control Updated 31 August 2016 Fermion Oy, Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland Tel. +358 10 4261 Fax: +358 9 452 1764 VAT Reg. No. FI18552129 e-mail: fermionSales@fermion.fi Contacts